Stealth Peptides Inc. Announces Results from Renal Impairment Clinical Study - Gamut News (press release) PDF Print
Gamut News (press release)
27, 2011 (Business Wire) — Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies, announced today the results of a Phase I renal impairment study with Bendavia™.

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.